scholarly journals The Effects of Fecal Microbiota Transplantation on the Symptoms and the Duodenal Neurogenin 3, Musashi 1, and Enteroendocrine Cells in Patients With Diarrhea-Predominant Irritable Bowel Syndrome

2021 ◽  
Vol 11 ◽  
Author(s):  
Tarek Mazzawi ◽  
Magdy El-Salhy ◽  
Gülen Arslan Lied ◽  
Trygve Hausken
Keyword(s):  
Stem Cells ◽  
Irritable Bowel Syndrome ◽  
Stem Cell ◽  
Fecal Microbiota Transplantation ◽  
Stem Cell Differentiation ◽  
Fecal Microbiota ◽  
Enteroendocrine Cells ◽  
Neurogenin 3 ◽  
Cell Densities ◽  
Irritable Bowel

IntroductionInteractions between the gut microbiota and enteroendocrine cells play important role in irritable bowel syndrome (IBS). Reduced stem cell densities and their differentiation into enteroendocrine cells may cause abnormal densities of the duodenal enteroendocrine cells in IBS patients.Materials and MethodsWe aimed to investigate the effects of fecal microbiota transplantation (FMT) on stem cell differentiation into enteroendocrine cells as detected by neurogenin 3, stem cells as detected by Musashi 1, and the enteroendocrine cells in the duodenum of IBS patients. The study included 16 IBS patients according to Rome III criteria. Four patients were excluded. The remaining patients (n = 12, four females and eight males) were divided according to the cause of IBS into post-infectious (n = 6) and idiopathic (n = 6) IBS. They completed the following questionnaires before and 3 weeks after FMT: IBS-Symptom Severity Scoring system (IBS-SSS) and IBS-Symptom Questionnaire (IBS-SQ). Feces donated by healthy relatives of the patients were transplanted via gastroscope. Biopsies were taken from the descending part of the duodenum at baseline and 3 weeks after FMT. They were immunostained for neurogenin 3, Musashi 1, and all types of duodenal enteroendocrine cells and quantified by computerized image analysis. Microbiota analyses of feces collected just before and 3 weeks after FMT were performed using GA-map™ Dysbiosis test (Genetic Analysis AS, Oslo, Norway).ResultsThe total scores for IBS-SSS and IBS-SQ were significantly improved 3 weeks after receiving FMT, P = 0.0009 and <0.0001, respectively. The stem cell densities of neurogenin 3 increased significantly following FMT (P = 0.0006) but not for Musashi 1 (P = 0.42). The cell densities of chromogranin A, cholecystokinin, gastric inhibitory peptide, serotonin, and somatostatin, but not for secretin, have significantly changed in both IBS groups after 3 weeks from receiving FMT.ConclusionMore than two-thirds of IBS patients experienced improvement in their symptoms parallel to changes in the enteroendocrine cells densities 3 weeks after FMT. The changes in the enteroendocrine cell densities do not appear to be caused by changes in the stem cells or their early progenitors rather by changes in the differentiation progeny as detected by neurogenin 3. The study was retrospectively registered at ClinicalTrials.gov (ID: NCT03333291).Clinical Trial RegistrationClinicalTrials.gov, identifier NCT03333291.

scholarly journals Abnormal Uroguanylin Immunoreactive Cells Density in the Duodenum of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Changes following Fecal Microbiota Transplantation

2020 ◽  
Vol 2020 ◽  
pp. 1-9 ◽  
Author(s):  
Tarek Mazzawi ◽  
Øystein Eikrem ◽  
Gülen Arslan Lied ◽  
Trygve Hausken
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Total Group ◽  
Guanylate Cyclase C ◽  
Rome Iii ◽  
Fresh Feces ◽  
Cell Densities ◽  
Irritable Bowel

Altered densities of enteroendocrine cells play an important role in patients with irritable bowel syndrome (IBS). Uroguanylin activates guanylate cyclase-C to regulate intestinal electrolyte and water transport. Aim. To quantify uroguanylin immunoreactive cells density in the duodenum of diarrhea-predominant IBS (IBS-D) patients compared to controls and to investigate the effect of fecal microbiota transplantation (FMT) on these cell densities. Method. Twelve patients with IBS-D according to Rome III criteria were included. The cause was identified as post infectious (PI, n=6) or idiopathic (n=6). They completed the IBS-symptom questionnaire before and 3 weeks after FMT. Thirty grams of fresh feces donated from healthy relatives were diluted with 60 ml normal saline and instilled via endoscope into the duodenum. Biopsies were taken from the patients’ duodenum before and 3 weeks after FMT. Duodenal biopsies taken from eight healthy controls were also included. The biopsies were immunostained for uroguanylin and quantified using computerized image analysis. Results. Uroguanylin immunoreactive cells were found both in duodenal villi and crypts in both controls and IBS-D patients. The densities of uroguanylin immunoreactive cells were significantly lower in the villi (P<0.0001) and higher in the crypts (P<0.0001) for the patients than the controls. Following FMT, the densities of uroguanylin immunoreactive cells for the total group and idiopathic subgroup decreased significantly in the duodenal crypts (P=0.049 and 0.04, respectively) but not in the villi. No significant changes were shown in the PI-IBS subgroups. The cells density in only the crypts correlated with diarrhea (r=0.97, P=0.001) and bloating (r=–0.91, P=0.01) in the PI-IBS subgroup before FMT and with abdominal pain (r=0.63, P=0.03) in the total group of IBS-D patients after FMT. Conclusion. Altered uroguanylin immunoreactive cells density was found in IBS-D patients compared to controls. Changes in these cells density following FMT correlated with IBS symptoms (diarrhea, bloating, and abdominal pain).

scholarly journals Engraftment of strictly anaerobic oxygen-sensitive bacteria in irritable bowel syndrome patients following fecal microbiota transplantation does not improve symptoms

Gut Microbes ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 1-16
Author(s):  
Patrick Denis Browne ◽  
Frederik Cold ◽  
Andreas Munk Petersen ◽  
Sofie Ingdam Halkjær ◽  
Alice Højer Christensen ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Strictly Anaerobic ◽  
Oxygen Sensitive ◽  
Irritable Bowel

Irritable bowel syndrome and transplantation of fecal microbiota. Review

2021 ◽  
Author(s):  
G. D. Fadieienko ◽  
O. Y. Gridnyev
Keyword(s):  
Irritable Bowel Syndrome ◽  
Fecal Microbiota Transplantation ◽  
Positive Outcome ◽  
Fecal Microbiota ◽  
Cochrane Library ◽  
Placebo Control ◽  
Global Improvement ◽  
Recurrent Clostridium Difficile Infection ◽  
Significant Difference ◽  
Irritable Bowel

Objective — to perform analysis of the literature data as regards the efficacy of the use of fecal microbiota transplantation (FMT) in patients with the irritable bowel syndrome (IBS). Materials and methods. The systematic review of the literature (PubMed, MEDLINE, Cochrane Library) has been performed to assess the results of investigation on the use of FMT in adult IBS patients. Results. Currently, FMT is a safe and highly successful method of treatment for recurrent Clostridium difficile infection, and possibility to use FMT in the treatment of other diseases is under investigation. The results of FMT treatment of patients with IBS are contradictory. A number of authors outline fairly high FMT efficacy when used for the treatment of patients with IBS, refractory to the standard methods: it varies from 36 % to 70 % with a duration of adequate symptoms’ relief up to 1 year. However, other authors indicate that the positive FMT clinical effect lasted from 8 weeks to 3 months, after which there was a gradual recovery of symptoms. At the same time, the researchers noted that mostly often the positive outcome was reached after FMT from donors with a higher number of streptococci in the feces. Still others point out that there was no sustained, at least 50‑point reduction in the severity of IBS symptoms from baseline. Some authors did not reveal the advantages of FMT over placebo control and even reported about the higher placebo efficacy. After data generalization no significant difference was revealed in the global improvement in IBS symptoms in patients receiving donor FM versus placebo. However, the attention is drawn to the relationship between the results of FMT with methodology. Indeed, several studies have shown that placebo capsules were more effective than capsules containing donor feces, whereas FMT from donor stool delivered by colonoscopy was superior to FMF from autologous stool. This may be due to the excipients, containing in the capsulated FMT. A number of researchers also indicated that the use of a super donor is necessary for successful FMT and that the response to FMT is dose dependent. Conclusions. To resolve the issue of the expediency of using FMT in routine clinical practice in patients with IBS, more qualitative controlled studies, involving large cohorts of IBS patients and long‑term follow‑up, are required.  

scholarly journals Fecal microbiota transplantation for patients with irritable bowel syndrome

Medicine ◽  
2018 ◽  
Vol 97 (40) ◽  
pp. e12661 ◽  
Author(s):  
Wenting Wen ◽  
Haibo Zhang ◽  
Junlong Shen ◽  
Luxia Wei ◽  
Shunong Shen
Keyword(s):  
Irritable Bowel Syndrome ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Irritable Bowel

scholarly journals Fecal microbiota transplantation for treatment of irritable bowel syndrome

2020 ◽  
Author(s):  
Sofie I Halkjaer ◽  
Bobby Lo ◽  
Frederik Cold ◽  
Alice Hoejer H Christensen ◽  
Lise Lotte Gluud ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Irritable Bowel

scholarly journals Research Progress in Fecal Microbiota Transplantation as Treatment for Irritable Bowel Syndrome

2019 ◽  
Vol 2019 ◽  
pp. 1-8 ◽  
Author(s):  
Yao Wang ◽  
Fengling Zheng ◽  
Shan Liu ◽  
Huanhuan Luo
Keyword(s):  
Irritable Bowel Syndrome ◽  
Intestinal Microbiota ◽  
Large Scale ◽  
Fecal Microbiota Transplantation ◽  
Clinical Manifestations ◽  
Fecal Microbiota ◽  
Research Progress ◽  
Future Research ◽  
Intestinal Microbes ◽  
Irritable Bowel

Irritable bowel syndrome is a functional disorder characterized by abdominal pain or discomfort associated with altered bowel habits. Due to the uncertainty of the pathogenesis of IBS and the diversity of its clinical manifestations, IBS cannot be completely cured. Increasing evidence suggests the key role of altered intestinal microbiota in the pathogenesis of IBS. Therefore, attention is being shifted to adjusting the changes in intestinal microbiota to control IBS symptoms. Fecal microbiota transplantation (FMT), antibiotics, probiotics, and synbiotics are currently often employed as treatment for IBS. And FMT is the most significant therapeutic efficacy with the least number of side effects. FMT provides a creative way to restore the abnormal gut microbiome in patients with IBS. But although current clinical studies confirm the effectiveness of FMT in the treatment of IBS, they are short-term studies of small samples, and there is still a lack of large-scale long-term studies. In this paper, we review the intestinal microbiota changes of IBS, the common methods of treating IBS with intestinal microbes, and the research status of FMT for the treatment of IBS. Finally, we put forward some opinions on the future research direction of FMT treatment of IBS.

Sign in / Sign up

Export Citation Format

Share Document